NCT00675441View on ClinicalTrials.gov

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Graft-versus-Host Disease

Interventions

DRUG

Lenalidomide

10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER